Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity.

Abstract

6041 Background: Dac is a potent, irreversible oral pan-HER tyrosine kinase inhibitor (TKI) with activity demonstrated in a multi-center phase II trial as first-line treatment in pts with recurrent...